Venetoclax for chronic lymphocytic leukemia in real-world care

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study enrolls patients with CLL who begin venetoclax as prescribed in routine clinical practice and collects clinical outcomes, healthcare resource use, and patient-reported outcomes. Patients may receive venetoclax alone or in combination with rituximab, obinutuzumab, ibrutinib, or acalabrutinib according to their physician's discretion. Data are collected at participating centers in Austria and follow participants over time to capture treatment effectiveness, adverse events, and cost-related information. No experimental treatments are assigned by the study and all medical decisions follow local labels and standard care.

Why it matters

Who can join: the full rules

Inclusion Criteria:

\- Participant with chronic lymphocytic leukemia (CLL) who start venetoclax therapy can be included in the study if treated as specified in the local label for any specific line of treatment.

Exclusion Criteria:

\- None

Where it's running

• Donauisar Klinikum Deggendorf /ID# 289012
  Deggendorf, Bavaria, Germany Recruiting
• Varisano Klinikum Frankfurt Hoechst /ID# 288028
  Frankfurt am Main, Hesse, Germany Recruiting
• Onkologische Schwerpunktpraxis Hanau /ID# 287948
  Hanau, Hesse, Germany Recruiting
• Gemeinschaftspraxis fuer Haematologie und Onkologie /ID# 281328
  Magdeburg, Germany Recruiting
• Réseau Hospitalier Neuchâtelois /ID# 227865
  Neuchâtel, Canton of Neuchâtel, Switzerland Recruiting
• Universitaetsklinikum St. Poelten /ID# 221152
  Sankt Pölten, Lower Austria, Austria Completed

+24 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Johannes Huelsenbeck
• Email: johannes.huelsenbeck@abbvie.com
• Phone: +49 611-1720-3036

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ibrutinib and Venetoclax in CLL/SLL: Long-Term Outcomes After Frontline CAPTIVATE

  This study follows people with CLL or SLL who previously received the ibrutinib plus venetoclax combination in CAPTIVATE to see how they do over time and what treatments they need if the disease returns.

  Recruiting European Research Initiative on CLL · Milan · NCT07774390

• Impact of Targeted Therapy on Cancer-Related Cognitive Impairment

  This study checks whether brain health and well‑being differ for people with leukemia who are starting or on TKI therapy compared with similar individuals without cancer or TKI exposure.

  Recruiting University of Rochester · Rochester, New York · NCT07638007

• BTK degrader plus BCL-2 inhibitor in untreated CLL/SLL

  This phase 2 study tests whether the BTK degrader BGB-16673 together with sonrotoclax can help people with newly diagnosed CLL/SLL.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT07508995

• Immune profiling during first-line pirtobrutinib treatment for CLL/SLL

  This will test pirtobrutinib as a first treatment for adults with CLL or SLL and see how it changes immune cells in the blood and lymph nodes.

  Recruiting Early Phase 1 National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07428707

• NX-5948 treatment for adults with CLL or SLL after prior BTK and BCL-2 inhibitor therapy

  NX-5948, an oral BTK degrader, will be tried to see if it helps adults with relapsed or refractory CLL or SLL who have already been treated with both BTK and BCL-2 inhibitors.

  Recruiting at 43 sites Phase 2 Nurix Therapeutics, Inc. · Phoenix, Arizona and 42 other locations · NCT07221500

• GT801 injection for adults with relapsed/refractory CD19-positive B-cell cancers and autoimmune hemolytic anemia

  This trial will test whether GT801 injections help adults with CD19-positive B-cell cancers (B-ALL, CLL, B-NHL) or autoimmune hemolytic anemia that have returned or not responded to prior treatments.

  Recruiting Early Phase 1 Grit Biotechnology · Zhengzhou, Henan and 1 other locations · NCT07205315

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.